. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2015 Feb 24;13(7):1293–1301.e5. doi: 10.1016/j.cgh.2015.02.017

Table 3. Rates and risk of serious or opportunistic infection in patients receiving anti-TNF combination therapy or monotherapy.

	Infliximab			Adalimumab			Combined Anti-TNF
Outcome	Rate in Combination Therapy (E/100 PY)	Rate in Mono-therapy (E/100 PY)	Adjusted HR^* (95% CI)	Rate in Combination Therapy (E/100 PY)	Rate in Mono-therapy (E/100 PY)	Adjusted HR^* (95% CI)	Adjusted HR^* (95% CI)
Serious infection
Without time-varying steroid adjustment	6.8	8.0	0.80 (0.48-1.34)	9.0	7.4	1.22 (0.61-2.45)	0.93 (0.88-1.34)
With time-varying steroid adjustment	6.8	8.0	0.80 (0.48-1.34)	9.0	7.4	1.14 (0.57-2.30)	0.91 (0.60-1.38)
Opportunistic infection
Without time-varying steroid adjustment	2.7	1.6	2.65 (1.05-6.66)	2.6	1.3	2.61 (0.63-10.8)	2.64 (1.21-5.73)
With time-varying steroid adjustment	2.7	1.6	2.60 (1.03-6.58)	2.6	1.3	2.19 (0.54-8.89)	2.51 (1.15-5.46)
Herpes zoster	2.2	1.0	3.38 (1.15-9.94)	1.8	0.7	2.64 (0.47-15.0)	3.16 (1.25-7.97)

Adjusted for prior immunomodulator use

Abbrevations: E, events; PY, person-years; HR, hazard ratio; CI, confidence interval